Liu et al. (2014) showed the constitutive activation of the STING pathway in peripheral blood monocytes and the upregulation of the reactivity to stimulating factors in fibroblast of patients with SAVI. In these fibroblasts, the Jak1/2 inhibitor baricitinib inhibiting the IFN pathway shows promising results (Kim et al., 2018; Liu et al., 2014; Sanchez et al., 2018). Here, IFNA1 is linked to STING-associated vasculopathy with onset in infancy.